拉米夫定联合甘利欣治疗慢性肝炎临床观察

目的观察联合甘利欣治疗慢性乙型肝炎、早期肝硬化的临床疗效。方法64例患者分为A组和B组，A组为单用拉米夫定给与100mg／d，疗程52周以上，B组联合使用甘利欣300mg／次。10d为1个疗程，结果联合甘利欣治疗组临床症状改善明显，降低ALT，增加HBeAg阴转例数，与单用拉米夫定比较差异有显著性（P〈0．05）。结论拉米夫定联合甘利欣治疗具有明显改善慢性乙型肝炎、早期肝硬化患者的临床症状，降低转氨酶。改善肝功能及抗肝纤维化的作用，对防止和治疗慢性肝炎和肝硬化有较好的疗效。

Clinical observation on the effect of Lamivudine combined with Ganlixin on Chronic Hepatitis B

Objective To observe the therapeutic effect of Lamivudine in combination with Ganlixin on chronic hepatitis B and early hepatoeirrhosis, Methods There 64 patients with chronic hepaittis B were randomly divided into groups A treated with Lamivudine only, 100g per day over 52 weeks and group B treated with Lamivudine and Ganlixin （the dose of ganlixin was 300g per day）. Results The symptoms in patients of group B was improved and the level of serum ALT reduced and the number of HbeAg - negative conversion rate increased as compared with that of group, showing significant differences （ P 〈 0.05）. Conclusion Lamivudine in combination with Ganiixin can improve the clinical symptoms of chronic hepatitis B with early symptom of hepatoeirrhosis, reduce aminopherase, regulate the liver＇s metabolic function, antifibrosis of liver and enhance the therapeutic effect.